Genedata has announced that Takeda Pharmaceutical Company expanded its collaboration with Genedata by licensing Genedata Expressionist for Genomic Profiling®. Takeda will use the solution to manage, analyze, and visualize massive amounts of raw data from next-generation sequencing (NGS), microarray, real time-PCR, and other genomic technologies. As an enterprise-level, high-throughput system that can simultaneously analyze thousands of experiments, Genedata Expressionist for Genomic Profiling integrates genomics, transcriptomics, epigenetics, and phenotypic data. Enabling Takeda to trace data and results while promoting standardization and reproducibility of experiments, Genedata Expressionist for Genomic Profiling helps Takeda advance its biomarker discovery projects.
“For many years, Takeda has relied on Genedata Expressionist for Mass Spectrometry for our biomarker discovery, and we have enjoyed a long-standing and collaborative relationship with Genedata,” noted a Takeda scientist in charge of bioinformatics research. “We searched for a solution to analyze NGS data that could be integrated with our other mass-spectrometry-based omics activities. Genedata Expressionist for Genomic Profiling uniquely handles high-throughput data and its capabilities for interactive genome visualization – essentially a highly-intuitive genome browser – will prove especially valuable to our NGS analysis.”
Pharmaceutical companies such as Takeda are using Genedata Expressionist for Genomic Profiling in a range of applications including: personalized medicine; biomarker discovery for predicting drug efficacy and toxicity; characterization of cell lines, xenografts and other model systems; and molecular diagnostics based on genomic and transcriptomic analyses.
Big Data – Easily Handled
Built on open and flexible client-server architecture, Genedata Expressionist for Genomic Profiling thrives on large and complex experimental data sets from all major vendors and technology platforms. It helps to bridge the gap between biology and statistics by making advanced statistical tools, which can analyze the most complex life science data, accessible to a wide range of users. These statistical tools advance the understanding of biological systems and diseases with support for some of the following technologies:
• Genomics/DNA-Seq: quantification of SNPs and InDels; chromosome rearrangement and gene fusion; quality control of called variants; annotation of variants with dbSNP or other external sources; functional annotation of variants; and analysis of copy number variations.
• Transcriptomics/RNA-Seq: gene, exon, and transcript-level quantification and expression analysis; identification of transcripts, novel genes, and exons; differential expression analysis; and detection of RNA-editing.
• Epigenomics/ChIP-Seq/Methyl-Seq: peak detection; annotation of detected peak regions; quantification of DNA methylation from ChIP or bisulfite treated DNA experiments; and identification and annotation of differentially methylated sites.
“Takeda is a leading, global pharmaceutical company with whom we are proud to be expanding our successful and long-term relationship,” said Dr. Othmar Pfannes, CEO of Genedata. “This collaboration validates our strategy to position Genedata Expressionist as an integration platform for a number of different omics technologies. Supporting NGS projects is a major focus for Genedata and we are committed to working with innovative companies such as Takeda who are pioneering NGS for improved healthcare.”